• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

全氟丙烷气体气动置换联合玻璃体内注射组织型纤溶酶原激活剂治疗中心性浆液性脉络膜视网膜病变局灶性激光光凝后视网膜下黄斑区出血

Pneumatic displacement with perfluoropropane gas and intravitreal tissue plasminogen activator for subretinal subfoveal hemorrhage after focal laser photocoagulation in central serous chorioretinopathy.

作者信息

Al Rubaie Khalid, Espinoza Juan V, Lasave Andres F, Savino-Zari Dario, Arevalo Fernando A, Arevalo J Fernando

机构信息

King Khaled Eye Specialist Hospital, Al-Oruba Street, P.O. Box 7191, Riyadh 11462, Saudi Arabia.

The Retina & Vitreous Service, Clínica Oftalmológica Centro Caracas, Avenida Panteon, Caracas 1010, Venezuela.

出版信息

Case Rep Ophthalmol Med. 2014;2014:592746. doi: 10.1155/2014/592746. Epub 2014 Nov 17.

DOI:10.1155/2014/592746
PMID:25485161
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4251634/
Abstract

Objective. To report the visual and anatomic outcomes of pneumatic displacement with perfluoropropane (C3F8) gas and intravitreal tissue plasminogen activator (IVTPA) for subretinal subfoveal hemorrhage after focal laser photocoagulation in central serous chorioretinopathy (CSCR). Method. Interventional, retrospective case report of one eye (one patient). Outcome measures included visual acuity (VA), central macular thickness (CMT), and size of the lesion at two weeks of followup. Fluorescein angiography (FA) and optical coherent tomography (OCT) were used to measure anatomic outcomes. Results. A 35-year-old man with history of chronic CSCR received focal laser photocoagulation in the right eye two days before presentation. At initial examination, VA was 20/200 (ETDRS chart), CMT was 398 μ, and a subretinal subfoveal hemorrhage was seen. Tissue plasminogen activator (tPA) at a dose of 25 µg/0.1 mL was injected intravitreally before intravitreal C3F8 injection, and prone positioning was indicated postoperatively. At 24 hours, the hemorrhage had been displaced inferiorly and VA improved to 20/100. Two weeks later, VA improved to 20/80, CMT decreased to 225 μ, and the hemorrhage decreased without foveal involvement. Conclusions. The technique seems safe and effective in treating visually significant subretinal subfoveal hemorrhage.

摘要

目的。报告在中心性浆液性脉络膜视网膜病变(CSCR)中,使用全氟丙烷(C3F8)气体和玻璃体内组织型纤溶酶原激活剂(IVTPA)进行气体置换治疗黄斑中心凹下视网膜下出血的视觉和解剖学结果。方法。对一只眼(一名患者)进行的介入性回顾性病例报告。观察指标包括随访两周时的视力(VA)、中心黄斑厚度(CMT)和病变大小。使用荧光素血管造影(FA)和光学相干断层扫描(OCT)测量解剖学结果。结果。一名有慢性CSCR病史的35岁男性在就诊前两天右眼接受了局部激光光凝治疗。初次检查时,视力为20/200(ETDRS视力表),CMT为398μm,可见黄斑中心凹下视网膜下出血。在玻璃体内注射C3F8之前,先向玻璃体内注射25μg/0.1mL的组织型纤溶酶原激活剂(tPA),术后采取俯卧位。24小时时,出血已向下移位,视力提高到20/100。两周后,视力提高到20/80,CMT降至225μm,出血减少且未累及黄斑中心凹。结论。该技术在治疗具有明显视觉影响的黄斑中心凹下视网膜下出血方面似乎安全有效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c67a/4251634/1371e67e1c71/CRIOPM2014-592746.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c67a/4251634/f8c8a1a5ba21/CRIOPM2014-592746.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c67a/4251634/f34fe09ffd5c/CRIOPM2014-592746.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c67a/4251634/1371e67e1c71/CRIOPM2014-592746.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c67a/4251634/f8c8a1a5ba21/CRIOPM2014-592746.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c67a/4251634/f34fe09ffd5c/CRIOPM2014-592746.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c67a/4251634/1371e67e1c71/CRIOPM2014-592746.003.jpg

相似文献

1
Pneumatic displacement with perfluoropropane gas and intravitreal tissue plasminogen activator for subretinal subfoveal hemorrhage after focal laser photocoagulation in central serous chorioretinopathy.全氟丙烷气体气动置换联合玻璃体内注射组织型纤溶酶原激活剂治疗中心性浆液性脉络膜视网膜病变局灶性激光光凝后视网膜下黄斑区出血
Case Rep Ophthalmol Med. 2014;2014:592746. doi: 10.1155/2014/592746. Epub 2014 Nov 17.
2
TISSUE PLASMINOGEN ACTIVATOR FOR SUBFOVEAL HEMORRHAGE DUE TO AGE-RELATED MACULAR DEGENERATION: Comparison of 3 Treatment Modalities.组织型纤溶酶原激活剂治疗年龄相关性黄斑变性所致黄斑下出血:三种治疗方式的比较
Retina. 2016 Oct;36(10):1860-5. doi: 10.1097/IAE.0000000000001030.
3
Pneumatic Displacement of Submacular Hemorrhage with Subretinal Air and Tissue Plasminogen Activator: Initial United States Experience.黄斑下出血的气体置换联合视网膜下空气及组织型纤溶酶原激活剂:美国的初步经验
Ophthalmol Retina. 2018 Mar;2(3):180-186. doi: 10.1016/j.oret.2017.07.012. Epub 2017 Sep 28.
4
Intravitreal Tissue Plasminogen Activator, Ranibizumab, and Gas Injection for Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy.眼内组织型纤溶酶原激活物、雷珠单抗联合气体注射治疗息肉样脉络膜血管病变伴黄斑下出血
Ophthalmology. 2016 Jun;123(6):1278-86. doi: 10.1016/j.ophtha.2016.01.035. Epub 2016 Mar 2.
5
Focal Laser Photocoagulation for Central Serous Chorioretinopathy in Under-Represented Populations: A Retrospective Case Series.聚焦激光光凝术治疗未充分代表人群的中心性浆液性脉络膜视网膜病变:一项回顾性病例系列研究
Case Rep Ophthalmol. 2022 Nov 28;13(3):991-998. doi: 10.1159/000527439. eCollection 2022 Sep-Dec.
6
Intravitreal tissue plasminogen activator, perfluoropropane (C3F8), and ranibizumab or photodynamic therapy for submacular hemorrhage secondary to wet age-related macular degeneration.眼内组织型纤溶酶原激活物、全氟丙烷(C3F8)以及雷珠单抗或光动力疗法治疗湿性年龄相关性黄斑变性继发的黄斑下出血。
Retina. 2013 Apr;33(4):846-53. doi: 10.1097/IAE.0b013e318271f278.
7
Navigated laser photocoagulation in patients with non-resolving and chronic central serous chorioretinopathy.导航激光光凝治疗非消退性和慢性中心性浆液性脉络膜视网膜病变患者。
Graefes Arch Clin Exp Ophthalmol. 2018 Sep;256(9):1581-1588. doi: 10.1007/s00417-018-4031-8. Epub 2018 Jun 6.
8
[Clinical results of intravitreal administration of tissue-type plasminogen activator (tPA) and gas for removal of subretinal hemorrhage in senile macular degeneration].玻璃体内注射组织型纤溶酶原激活剂(tPA)联合气体治疗老年黄斑变性视网膜下出血的临床结果
Klin Monbl Augenheilkd. 2000 Jan;216(1):33-9. doi: 10.1055/s-2000-10513.
9
A Case of Pneumatic Displacement with Gas Tamponade Performed for Macular Subretinal Hemorrhage Complicating Vogt-Koyanagi-Harada Disease.1例针对伏格特-小柳-原田病并发黄斑视网膜下出血行气体填充性气体填塞术的病例。
Case Rep Ophthalmol. 2020 Mar 19;11(1):143-150. doi: 10.1159/000506436. eCollection 2020 Jan-Apr.
10
Management of submacular hemorrhage with intravitreous tissue plasminogen activator injection and pneumatic displacement.玻璃体内注射组织型纤溶酶原激活剂及气体置换治疗黄斑下出血
Ophthalmology. 1999 Oct;106(10):1900-6; discussion 1906-7. doi: 10.1016/S0161-6420(99)90399-8.

本文引用的文献

1
Photodynamic therapy for central serous chorioretinopathy.中心性浆液性脉络膜视网膜病变的光动力疗法
Eye (Lond). 2014 Aug;28(8):944-57. doi: 10.1038/eye.2014.134. Epub 2014 Jun 20.
2
Long-term visual outcome and its predictive factors following treatment of acute submacular hemorrhage with intravitreous injection of tissue plasminogen factor and gas.玻璃体内注射组织纤溶酶原因子及气体治疗急性黄斑下出血后的长期视力转归及其预测因素
J Ocul Pharmacol Ther. 2014 Sep;30(7):567-72. doi: 10.1089/jop.2013.0135. Epub 2014 May 12.
3
Single-session combined photodynamic therapy with verteporfin and intravitreal anti-vascular endothelial growth factor therapy for chronic central serous chorioretinopathy: a pilot study at 12-month follow-up.
单次联合光动力疗法与维替泊芬和玻璃体内抗血管内皮生长因子治疗慢性中心性浆液性脉络膜视网膜病变:12 个月随访的初步研究。
Graefes Arch Clin Exp Ophthalmol. 2011 Aug;249(8):1159-66. doi: 10.1007/s00417-011-1651-7. Epub 2011 Mar 30.
4
A pilot study of intravitreal bevacizumab for the treatment of central serous chorioretinopathy (case reports).玻璃体内注射贝伐单抗治疗中心性浆液性脉络膜视网膜病变的初步研究(病例报告)
Graefes Arch Clin Exp Ophthalmol. 2008 Sep;246(9):1235-9. doi: 10.1007/s00417-008-0856-x. Epub 2008 Jun 4.
5
Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: one-year results of a prospective study.安全性增强的光动力疗法治疗慢性中心性浆液性脉络膜视网膜病变:一项前瞻性研究的一年结果
Retina. 2008 Jan;28(1):85-93. doi: 10.1097/IAE.0b013e318156777f.
6
Transpupillary thermotherapy for chronic central serous chorioretinopathy.经瞳孔温热疗法治疗慢性中心性浆液性脉络膜视网膜病变。
Graefes Arch Clin Exp Ophthalmol. 2006 Aug;244(8):1045-51. doi: 10.1007/s00417-005-0175-4. Epub 2006 Jan 13.
7
Intravitreal tissue plasminogen activator and pneumatic displacement of submacular hemorrhage secondary to retinal artery macroaneurysm.玻璃体内注射组织型纤溶酶原激活剂与视网膜动脉大动脉瘤继发黄斑下出血的气体置换术
J Ocul Pharmacol Ther. 2005 Feb;21(1):62-7. doi: 10.1089/jop.2005.21.62.
8
Chronic central serous chorioretinopathy: photodynamic therapy.慢性中心性浆液性脉络膜视网膜病变:光动力疗法
Am J Ophthalmol. 2004 Jun;137(6):1073-80. doi: 10.1016/j.ajo.2004.01.043.
9
Tissue plasminogen activator plus gas injection in patients with subretinal hemorrhage caused by age-related macular degeneration: predictive variables for visual outcome.组织型纤溶酶原激活剂联合气体注射治疗年龄相关性黄斑变性所致视网膜下出血:视力预后的预测变量
Graefes Arch Clin Exp Ophthalmol. 2002 Sep;240(9):717-20. doi: 10.1007/s00417-002-0516-5. Epub 2002 Jul 24.
10
Intravitreous injection of tissue plasminogen activator and gas in the treatment of submacular hemorrhage under various conditions.玻璃体腔内注射组织型纤溶酶原激活剂和气体在各种情况下治疗黄斑下出血。
Ophthalmology. 2001 Aug;108(8):1485-92. doi: 10.1016/s0161-6420(01)00648-0.